Drug intelligence / Profile preview

isovalerylspiramycin I

Development stage
Preclinical
Lead developer
Shen Yang Fuyang Medicine Technology
Modality
RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral
01

Overview

Isovalerylspiramycin I is a semi-synthetic macrolide antibiotic and a principal active component of carrimycin, derived by acylating the 4'-OH group of spiramycin with an isovaleryl side chain. It features a 16-membered lactone ring structure and exhibits both antibacterial and anticancer properties. Mechanistically, it acts as an inhibitor of topoisomerase 1 (TOP1), directly binding to this enzyme, thereby inhibiting DNA replication in cancer cells. Additionally, it suppresses the ATR/CHEK1 DNA damage repair pathway, leading to increased DNA damage and apoptosis in tumor cells. Isovalerylspiramycin I has demonstrated efficacy against various solid tumors (including osteosarcoma) and shows potential antiviral activity against enterovirus, herpes virus, influenza virus, and HIV[2][3][5][10].

Other names
ISP-I
02

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on isovalerylspiramycin I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on isovalerylspiramycin I.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call